

## INTRODUCTION

The opioid crisis was declared a public health emergency in 2017 and has been exacerbated by the COVID-19 pandemic. Provisional CDC data from Jan 2020-Jan 2021 shows 60,866 deaths from opioid overdose, a 27% increase in deaths from 2017. Expanding access to treatment for opioid use disorder (OUD) continues to be a key priority emphasized by the CDC. Integrating buprenorphine therapy in primary care has long been identified as a promising strategy to improve access.

## OBJECTIVE


Develop a curriculum to train residents in buprenorphine therapy for OUD, in a primary care clinic within the John Muir Health system.

## METHODS

To integrate buprenorphine training into our residency clinic, we addressed multiple areas across our healthcare organization:

<b>RESIDENT PROVIDERS</b>	Incorporate "X" waiver training into curriculum. Foster resident advocacy in health system.
<b>FACULTY</b>	Incorporate "X" waiver training into faculty administrative time. Identify community resources for expert consultation.
<b>CLINICAL PROTOCOLS</b>	Develop buprenorphine protocols with guidance from experts in the community, that includes regular in-person and telehealth visits, home induction, CURES and urine toxicology monitoring, and after-hours management.
<b>PSYCHOSOCIAL SUPPORT</b>	Collaborate with our integrative behavioral health team and identify community resources for OUD support.
<b>PRACTICE MANAGEMENT</b>	Create schedule templates, order supplies, and train support staff.
<b>PHARMACY SUPPORT</b>	Identify a 24-hour pharmacy partner that stocks and is familiar with buprenorphine.
<b>IT SUPPORT</b>	Make changes to electronic health system to support new clinical protocols, ie. ordering point of care drug screen. Confirmed 42 CFR Part 2 restrictions do not apply to buprenorphine therapy in integrated primary care setting.
<b>BILLING ISSUES</b>	Identify OUD billing issues specific to insurance plans common in our patient population, including coverage for visits, buprenorphine, and naloxone.
<b>INTER-DEPARTMENTAL COLLABORATION</b>	In conjunction with the Behavioral Health department and Emergency department, hire a Substance Use Navigator for care coordination needs related to substance use across the John Muir Health system.

## RESULTS



**Figure 2. Buprenorphine induction schedule in residency clinic**  
Outpatient rotations have reserved timeslots, which are released for other visits if no induction is scheduled.

	MON	TUES	WED	THURS	FRI	WEEKEND
<b>Patient contact</b>	Intake (1 hr)	Induction f/u (30 min)	Induction f/u (30 min)	Psychosocial check-in (30 min)	Induction f/u (30 min)	On-call resident
<b>Type</b>	Office visit	Videovisit	Videovisit	Phone call	Videovisit	Phone call prn

**Figure 3. Management of patients on buprenorphine**

Patient needs	Treatment overview
<b>Scheduled to start induction</b>	See induction schedule for first week above. Baseline CMP, Utox, urine hCG. CURES check. HIV/Hep B/Hep C if hx intravenous drug abuse.
<b>Recently started induction in ED</b>	Start patient on home induction protocol in ED, schedule for next available induction followup visit in clinic. Coordinated by Substance Use Navigator.
<b>Started induction in past month</b>	After induction schedule for first week, weekly visits and check-in phone calls for psychosocial needs. Random Utox within the first month.
<b>Stable on a dose and was induced more than 1 month ago</b>	Depending on patient stability and risk factors, may change to monthly visits. Check-in phone calls for psychosocial needs depending on access to other behavioral health support. Random Utox every 2 months, CURES check every 4 months. LFTs 3 months after induction, then annually.
<b>Desires to wean off buprenorphine</b>	Slow taper as tolerated, increase frequency of visits and check-in phone calls for psychosocial needs.

## DISCUSSION

To prepare residents to treat OUD with buprenorphine, we (1) provided opportunities for X-waiver licensure, and (2) integrated buprenorphine therapy into our residency clinic. Major barriers included administrative hurdles in a health system that is unfamiliar with OUD treatment in primary care, and provider hesitancy due to inexperience. The COVID-19 pandemic caused setbacks, including a hiring freeze that delayed onboarding a Substance Use Navigator for care coordination. However, it also presented a new opportunity by popularizing telehealth visits, which is helpful for home inductions. In addition to X-waiver training and developing clinical protocols, primary care programs planning to start buprenorphine therapy should give consideration to administrative issues (ie. practice management, IT, billing), addressing provider hesitancy, and fostering collaborations (ie. emergency department, behavioral health).